Your session is about to expire
← Back to Search
EQ001 for Graft-versus-Host Disease (EQUATE Trial)
EQUATE Trial Summary
This trial is testing a new drug to treat aGVHD, a condition where the transplanted donor cells attack the patient's cells. They will be testing how safe and well tolerated the drug is, how it works in the body, and how effective it is at treating aGVHD.
- Graft-versus-Host Disease
- Acute Graft-versus-Host Disease
EQUATE Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowEQUATE Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.EQUATE Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
What other research initiatives exist related to EQ001?
"Currently, two medical studies are underway examining the potential of EQ001. Neither is in Phase 3 yet. Bronx, New york serves as the hub for these trials with 45 separate locations running them."
What is the current cohort size for this research endeavor?
"To successfully complete the trial, 100 qualified individuals need to enroll. These volunteers can select from two centers of excellence, Washington University and Barnes Jewish Heart & Vascular Center in Saint Louis or Dana-Farber Cancer Institute located in Boston."
Is this an inaugural trial for its kind?
"EQ001 has been subject to clinical investigations since 2019, with the earliest trial conducted by Biocon Limited. After its successful Phase 1 & 2 approval in 2019 following a study involving 100 patients, there are currently two active trials for EQ001 spread across 32 cities and 3 countries."
Are there various locations conducting this research in the city?
"Washington University and Barnes Jewish Heart & Vascular Center, Dana-Farber Cancer Institute, TriStar Centennial Medical Centre (SCRI), as well as 15 other centres in the United States of America are all participating sites for this clinical trial."
Are there any vacancies available for participants in this clinical experiment?
"Affirmative. Information present on clinicaltrials.gov reveals that this research study is actively enrolling candidates as of now; it was initially advertised on July 15th, 2019 and the most recent update happened October 1st 2021. The trial requires 100 participants to be recruited from 15 medical centres."
What are the primary aims of this medical investigation?
"The primary endpoint of the research is to assess the Treatment Emergent Adverse Events by Day 337. Secondary objectives involve measuring half-life, total exposure, area under curve (AUC) and maximum serum drug concentration for EQ001."
Share this study with friends
Copy Link
Messenger